Stereotactic ablative radiotherapy (SABR) for early stage, medically inoperable non-small cell lung cancer (NSCLC): initial outcomes from 2 years' experience at the Oxford Cancer Centre, Oxford University Hospitals NHS Trust
Hill E., Higgins G., Vallis K., Stuart R., Drummond L., Buckle A., Panakis N.